Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.42 USD

91.42
364,986

-0.16 (-0.18%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for HAE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Haemonetics Corporation falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 179 284 260 192 137
Receivables 207 179 159 128 165
Notes Receivable 0 0 0 0 0
Inventories 317 259 293 323 270
Other Current Assets 66 47 44 51 31
Total Current Assets 769 770 756 694 604
Net Property & Equipment 311 311 258 218 253
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 8 5 4 6 4
Intangibles 971 742 778 832 344
Deposits & Other Assets 136 107 63 71 62
Total Assets 2,196 1,935 1,860 1,820 1,267
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable 10 12 214 17 77
Accounts Payable 73 64 58 50 51
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 81 64 49 48 49
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 136 112 121 139 98
Total Current Liabilities 300 252 442 254 275
Mortgages 0 0 0 0 0
Deferred Taxes/Income 63 36 29 44 11
Convertible Debt 0 0 0 0 0
Long-Term Debt 798 754 559 691 306
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 75 75 80 100 89
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,236 1,117 1,110 1,088 680
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 635 595 572 603 553
Retained Earnings 360 253 202 158 79
Other Equity -36 -30 -26 -30 -45
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 960 818 749 732 587
Total Liabilities & Shareholder's Equity 2,196 1,935 1,860 1,820 1,267
Total Common Equity 960 818 749 732 587
Shares Outstanding 50.70 50.40 51.10 50.80 50.30
Book Value Per Share 18.93 16.23 14.67 14.40 11.67

Fiscal Year End for Haemonetics Corporation falls in the month of March.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 179 194 351 286
Receivables NA 207 212 174 177
Notes Receivable NA 0 0 0 0
Inventories NA 317 304 286 289
Other Current Assets NA 66 55 55 50
Total Current Assets NA 769 765 866 802
Net Property & Equipment NA 311 319 308 304
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 8 5 5 5
Intangibles NA 971 984 716 734
Deposits & Other Assets NA 136 127 117 117
Total Assets NA 2,196 2,200 2,011 1,962
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 10 14 14 14
Accounts Payable NA 73 57 80 78
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 81 59 46 33
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 136 132 125 112
Total Current Liabilities NA 300 262 264 237
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 63 62 35 37
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 798 857 749 751
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 76 70 72
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,236 1,257 1,118 1,098
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 635 627 617 610
Retained Earnings NA 360 340 309 284
Other Equity NA -36 -24 -33 -30
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 960 943 894 865
Total Liabilities & Shareholder's Equity NA 2,196 2,200 2,011 1,962
Total Common Equity 0 960 943 894 865
Shares Outstanding 50.90 50.70 50.70 50.70 50.60
Book Value Per Share 0.00 18.93 18.61 17.63 17.09